Share-based Payment Arrangement, Expense of AVENUE THERAPEUTICS, INC. from 31 Dec 2015 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
AVENUE THERAPEUTICS, INC. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2015 to 30 Sep 2025.
  • AVENUE THERAPEUTICS, INC. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $163,000, a 51% decline year-over-year.
  • AVENUE THERAPEUTICS, INC. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $1,045,000, a 2.4% increase year-over-year.
  • AVENUE THERAPEUTICS, INC. annual Share-based Payment Arrangement, Expense for 2024 was $1,236,000, a 36% increase from 2023.
  • AVENUE THERAPEUTICS, INC. annual Share-based Payment Arrangement, Expense for 2023 was $906,000, a 40% increase from 2022.
  • AVENUE THERAPEUTICS, INC. annual Share-based Payment Arrangement, Expense for 2022 was $649,000.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

AVENUE THERAPEUTICS, INC. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $1,045,000 $163,000 -$168,000 -51% 01 Jul 2025 30 Sep 2025 10-Q 13 Nov 2025 2025 Q3
Q2 2025 $1,213,000 $175,000 -$17,000 -8.9% 01 Apr 2025 30 Jun 2025 10-Q 14 Aug 2025 2025 Q2
Q1 2025 $1,230,000 $185,000 -$6,000 -3.1% 01 Jan 2025 31 Mar 2025 10-Q 15 May 2025 2025 Q1
Q4 2024 $1,236,000 $522,000 +$215,000 +70% 01 Oct 2024 31 Dec 2024 10-K 31 Mar 2025 2024 FY
Q3 2024 $1,021,000 $331,000 -$230,000 -41% 01 Jul 2024 30 Sep 2024 10-Q 13 Nov 2025 2025 Q3
Q2 2024 $1,251,000 $192,000 +$165,000 +611% 01 Apr 2024 30 Jun 2024 10-Q 14 Aug 2025 2025 Q2
Q1 2024 $1,086,000 $191,000 +$180,000 +1636% 01 Jan 2024 31 Mar 2024 10-Q 15 May 2025 2025 Q1
Q4 2023 $906,000 $307,000 01 Oct 2023 31 Dec 2023 10-K 31 Mar 2025 2024 FY
Q3 2023 $561,000 +$536,000 +2144% 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2024 2024 Q3
Q2 2023 $27,000 -$16,000 -37% 01 Apr 2023 30 Jun 2023 10-Q 09 Aug 2024 2024 Q2
Q1 2023 $11,000 01 Jan 2023 31 Mar 2023 10-Q 15 May 2024 2024 Q1
Q3 2022 $25,000 01 Jul 2022 30 Sep 2022 10-Q 13 Nov 2023 2023 Q3
Q2 2022 $43,000 01 Apr 2022 30 Jun 2022 10-Q 11 Aug 2023 2023 Q2
Q1 2018 $100,000 $0 -$100,000 -100% 01 Jan 2018 31 Mar 2018 10-Q 03 May 2018 2018 Q1
Q4 2017 $200,000 $0 -$79,000 -100% 01 Oct 2017 31 Dec 2017 10-K 01 Mar 2018 2017 FY
Q3 2017 $279,000 $0 -$70,000 -100% 01 Jul 2017 30 Sep 2017 10-Q 09 Nov 2017 2017 Q3
Q2 2017 $349,000 $100,000 +$30,000 +43% 01 Apr 2017 30 Jun 2017 10-Q 11 Aug 2017 2017 Q2
Q1 2017 $319,000 $100,000 +$19,000 +23% 01 Jan 2017 31 Mar 2017 10-Q 03 May 2018 2018 Q1
Q4 2016 $300,000 $79,000 01 Oct 2016 31 Dec 2016 10-K 01 Mar 2018 2017 FY
Q3 2016 $70,000 01 Jul 2016 30 Sep 2016 10-Q 09 Nov 2017 2017 Q3
Q2 2016 $70,000 01 Apr 2016 30 Jun 2016 10-Q 11 Aug 2017 2017 Q2
Q1 2016 $81,000 01 Jan 2016 31 Mar 2016 10-Q 12 May 2017 2017 Q1

AVENUE THERAPEUTICS, INC. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $1,236,000 +$330,000 +36% 01 Jan 2024 31 Dec 2024 10-K 31 Mar 2025 2024 FY
2023 $906,000 +$257,000 +40% 01 Jan 2023 31 Dec 2023 10-K 31 Mar 2025 2024 FY
2022 $649,000 01 Jan 2022 31 Dec 2022 10-K 18 Mar 2024 2023 FY
2017 $200,000 -$100,000 -33% 01 Jan 2017 31 Dec 2017 10-K 01 Mar 2018 2017 FY
2016 $300,000 +$200,000 +200% 01 Jan 2016 31 Dec 2016 10-K 01 Mar 2018 2017 FY
2015 $100,000 09 Feb 2015 31 Dec 2015 10-K 01 Mar 2018 2017 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.